今年1月27日，津药药业收到天津证监局《行政监管措施决定书》，监管部门查明公司存在两大违规问 题：一是部分外购技术项目采用制式合同，对合作方违约责任约定不明确，合同内容不规范；二是未能 及时识别部分研发项目终止风险，导致预付款收回不及时。上述行为违反了《上市公司治理准则》及 《企业内部控制应用指引》相关规定。依据核查结果，天津证监局对津药药业采取责令改正监管措施， 同时对5名现任及前任高管出具警示函。 针对上述问题，津药药业成立专项整改工作领导小组，统筹推进整改落实，制定了针对性解决方案。在 合同管理方面，公司已完成研发类合同范本梳理，正在推进修订后范本的应用，同时优化完善合同审核 流程，明确业务部门与法务合规部双重审核职责，实现研发相关合同审核全覆盖。在研发项目管理及资 金管控方面，公司已完成研发项目预付款专项清理，截至2025年10月15日，涉事预付款已全部收回；同 时建立健全研发项目风险管控机制，出台《津药药业科研项目管理SMP》，将预付款支付与项目风险评 估挂钩，强化财务动态监控与风险预警。 津药药业表示，针对《决定书》指出的问题，公司已制定有效的整改措施，目前已完成主要整改工作。 为巩固整改成效，建 ...

Market Performance - The pharmaceutical sector increased by 0.84% on February 25, 2025, outperforming the CSI 300 index by 0.24 percentage points, ranking 14th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, other biological products (+2.39%), hospitals (+2.04%), and medical consumables (+1.58%) showed the best performance, while offline pharmacies (+0.32%), in vitro diagnostics (+0.33%), and medical research outsourcing (+0.34%) lagged behind [1] - Top three gainers in individual stocks were Changchun High-tech (+10.00%), Aidi Te (+9.03%), and Changshan Pharmaceutical (+8.87%); top three losers were Frontier Biotech (-4.09%), Baile Tianheng (-3.62%), and Shuoshi Biotech (-2.97%) [1] Industry News - Immedica announced that the FDA has accelerated the approval of Loargys for the treatment of hyperargininemia in patients aged 2 years and older with arginase 1 deficiency (ARG1-D), based on positive results from the Phase 3 PEACE trial [2] - The trial showed that the geometric mean of plasma arginine (pArg) in patients treated with Loargys decreased significantly from 354.0 μmol/L to 86.4 μmol/L by week 24 [2] - Loargys is a recombinant human arginase that can rapidly and sustainably lower plasma arginine and its toxic metabolites while improving clinical symptoms; it has already been approved in the EU and the UK [2] Company News - Sino Medical (688108) reported a revenue of 525 million yuan for 2025, a year-on-year increase of 14.53%, with a net profit attributable to shareholders of 47 million yuan, up 3057.05%, and a net profit of 34 million yuan after deducting non-recurring items, up 293.82% [3] - United Imaging (688271) announced a revenue of 13.821 billion yuan for 2025, a 34.18% increase year-on-year, with a net profit of 1.888 billion yuan, up 49.60%, and a net profit of 1.788 billion yuan after deducting non-recurring items, up 77.01% [3] - Huyou Pharmaceutical (688553) received notification from the FDA that its new drug applications for etoposide injection and fluorouracil injection have been approved, facilitating the company's expansion into the U.S. market [3] - Aibo Medical (688050) announced plans to acquire 68.31% of Demai Medical for 683 million yuan, with Demai Medical being a leading company in sports medicine; this acquisition will make it a subsidiary of Aibo Medical [3]

2026 年 02 月 25 日 行业日报 看好/维持 医药 医药 太平洋医药日报（20260225）：酶替代疗法 Loargys 获 FDA 批准 ◼ 走势比较 (10%) (2%) 6% 14% 22% 30% 25/2/25 25/5/9 25/7/21 25/10/2 25/12/14 26/2/25 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 <<太平洋医药日报（20260224）： Molbreevi 获 FDA 授予优先审评资 格>>--2026-02-25 <<太平洋医药日报（20260213）：安进 Inebilizumab 获欧盟批准>>--2026- 02-15 <<太平洋医药日报（20260212）：默沙 东 Keytruda 获 FDA 批准新适应症>>- -2026-02-15 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 电话： E-MAIL：zha ...

近日，汇宇制药发布公告称，收到美国食品药品监督管理局（简称"美国 FDA"）的通知，公司向美国 FDA 申报的依托泊苷注射液、氟尿嘧啶注射液的新药申请（NDA）均已获得批准，意味着公司可以生 产并通过海外合作方在美国市场销售前述产品。 （汇宇制药公告） 公告提到，获得FDA批准后，将有助于公司拓展美国市场的销售，强化产品供应链，并丰富产品梯队， 为国际市场的可持续发展奠定基础。虽然公司已开始上市销售的前期准备，但由于产品的非唯一性及同 类产品的竞争，未来收入存在较大不确定性。 ...

Policy Developments - Shandong Province held a meeting on February 25, 2026, to address corruption and misconduct in the healthcare sector, emphasizing the need for a coordinated effort to safeguard medical insurance funds and promote orderly development in healthcare [1] Drug and Device Approvals - Kanghong Pharmaceutical received approval from the National Medical Products Administration for clinical trials of KHN707 tablets for insomnia, a class 1 innovative drug [2] - Fosun Pharma's subsidiary received approval for clinical trials of Rumaine® (generic name: Luwomeitini tablets) for advanced non-small cell lung cancer, with global sales of MEK1/2 inhibitors projected to reach approximately $2.068 billion in 2024 [3] - China Pharmaceutical announced that its subsidiary received a drug registration certificate for injectable fosfomycin, aimed at treating acute bacterial skin and soft tissue infections [4] - Huyou Pharmaceutical received FDA approval for its new drug applications for Etoposide injection and Fluorouracil injection, enabling sales in the U.S. market [5] - Kangfang Biotech's application for the monoclonal antibody AK120 was accepted for review by the National Medical Products Administration [6] Industry Developments - Junshi Bioscience and Deqi Pharmaceuticals entered a strategic collaboration to explore the combined treatment potential of JS207 and ATG-037 for cancer patients in mainland China [8] - Illumina announced an 18-month innovation upgrade roadmap for the NovaSeq X sequencer, enhancing its capabilities and productivity [9] Capital Market Activities - Sainuo Medical announced a share repurchase plan with a total amount between 15 million and 30 million yuan, aimed at employee stock ownership plans or equity incentives [10] Financial Data - United Imaging reported a net profit of 1.888 billion yuan for 2025, a year-on-year increase of 49.60%, driven by new product launches and growth in overseas business [11] - Xiansheng Pharmaceutical projected a revenue of approximately 7.7 billion to 7.8 billion yuan for the 2025 fiscal year, with a net profit increase of 80.1% to 93.9% [12] - Sainuo Medical reported a net profit of 47.29 million yuan for 2025, a significant increase of 3,057.05% year-on-year, attributed to revenue growth and cost management [13]

汇宇制药表示，公司研发的依托泊苷注射液、氟尿嘧啶注射液获得美国FDA批准，标志着具备了在美国 市场销售产品的资格，有利于公司拓展美国市场的销售、强化产品供应链、丰富产品梯队，为国际市场 的可持续发展进一步夯实了基础。 北京商报讯（记者 丁宁）2月25日晚间，汇宇制药（688553）发布公告称，公司于近日收到美国食品药 品监督管理局（以下简称"美国FDA"）的通知，公司向美国FDA申报的依托泊苷注射液、氟尿嘧啶注射 液的新药申请均已获得批准，意味着公司可以生产并通过海外合作方在美国市场销售前述产品。 ...

Group 1: Financial Performance Highlights - Lante Optics achieved a revenue of 1.536 billion yuan in 2025, a year-on-year increase of 48.52%, with a net profit of 388 million yuan, up 76.09% [1] - United Imaging reported a revenue of 13.82 billion yuan for 2025, reflecting a 34.18% year-on-year growth, and a net profit of 1.888 billion yuan, up 49.60% [2] - Hengxuan Technology's revenue reached 3.525 billion yuan, an 8.02% increase, with a net profit of 588 million yuan, up 27.75% [3] - Nanya New Materials reported a significant net profit increase of 378.65%, reaching 241 million yuan, with revenue of 5.228 billion yuan, up 55.52% [4] - Yancoal Australia, a subsidiary of Yancoal Energy, reported a revenue of 5.949 billion AUD and a net profit of 4.4 billion AUD for 2025 [5] - Hanlan Co. reported a revenue of 10.467 billion yuan, a 13.04% increase, but a net profit decline of 9.59% to 592 million yuan [10][11] - Transsion Holdings experienced a revenue decline of 4.50% to 65.623 billion yuan, with a net profit drop of 53.43% to 2.584 billion yuan [14] - Huachuang Technology achieved a revenue of 628 million yuan, a 2.78% increase, with a net profit of 42.678 million yuan, up 89.45% [21] - Aiko Optoelectronics reported a revenue of 440.311 million yuan, a 77.36% increase, with a net profit of 64.0919 million yuan, up 307.63% [34] - Chip Microelectronics achieved a revenue of 1.408 billion yuan, a 47.61% increase, with a net profit of 290 million yuan, up 80.42% [35] - Shenkong Co. reported a revenue of 443 million yuan, a 46.26% increase, with a net profit of 101 million yuan, up 146.54% [36] - Qinda Environmental reported a revenue of 2.042 billion yuan, a 55.42% increase, with a net profit of 181 million yuan, up 94.62% [39] Group 2: Corporate Developments - Huilong New Materials announced that its actual controller is planning a significant matter that may lead to a change in company control, resulting in a stock suspension [6] - Fangzheng Securities disclosed that its shareholder China Cinda did not reduce its shareholding as planned during the designated period [7] - Lingyi Technology plans to invest 20 million yuan in a partnership with several investment firms [8] - Longbai Group's subsidiary has partially resumed production after a safety incident [9] - Fuda Co. plans to reduce its repurchased shares by up to 1% through centralized bidding [13] - Fuxing Pharmaceutical's subsidiary received approval for clinical trials of a new drug for lung cancer [15] - Beixin Road and Bridge won a bid for a highway reconstruction project worth 751 million yuan [16] - Songsheng Co. established a joint venture with a registered capital of 30 million yuan, focusing on digital energy products [17] - Moxinlin reported a revenue of 577 million yuan, a 20.98% increase, with a net profit of 55.8745 million yuan, up 22.69% [18] - Zhuhai Beer reported a revenue of 5.878 billion yuan, a 2.56% increase, with a net profit of 903 million yuan, up 11.42% [24] - Honghua Digital reported a revenue of 2.308 billion yuan, a 28.90% increase, with a net profit of 529 million yuan, up 27.63% [25] - Xinfeng Pharmaceutical received FDA approval for two injectable drugs [26] - Jiazhe New Energy's project for green hydrogen production received regulatory approval [27] - Chip Microelectronics reported a revenue of 5.24 billion yuan, a 29.48% increase, with a net profit of 302 million yuan, up 36.1% [28] - Debang Co. completed the cash settlement process for its delisting [29] - Xingfu Electronics reported a revenue of 1.475 billion yuan, a 29.72% increase, with a net profit of 208 million yuan, up 30.37% [30] - Longda Food announced the resignation of its general manager due to work adjustments [31] - Bohai Chemical reported that some fundraising projects have commenced production [32] - Shengke Communication reported a net loss of 150 million yuan for 2025 [33] - Jin Cheng Pharmaceutical's subsidiaries received drug registration certificates for two products [37] - Jinpu Titanium Industry announced the resumption of production at its subsidiary [38] - Zhigao Electric's subsidiary won a bid for a project worth 182 million yuan [40]

公司研发的依托泊苷注射液、氟尿嘧啶注射液获得美国FDA批准，标志着具备了在美国市场销售产品的 资格，有利于公司拓展美国市场的销售、强化产品供应链、丰富产品梯队，为国际市场的可持续发展进 一步夯实了基础。 格隆汇2月25日丨汇宇制药(688553.SH)公布，公司于近日收到美国食品药品监督管理局（以下简称"美 国FDA"）的通知，公司向美国FDA申报的依托泊苷注射液、氟尿嘧啶注射液的新药申请（NDA）均已 获得批准，意味着公司可以生产并通过海外合作方在美国市场销售前述产品。 依托泊苷注射液是一种拓扑异构酶抑制剂，与其它化疗和/或免疫治疗联合使用，适用于治疗以下成年 患者：1.难治性睾丸癌；2.小细胞肺癌。氟尿嘧啶注射液适用于治疗：1.结肠癌和直肠癌；2.乳腺癌；3. 胃腺癌；4.胰腺癌。 ...

每经AI快讯，2月25日，汇宇制药(688553.SH)公告称，公司于近日收到美国FDA的通知，公司向美国 FDA申报的依托泊苷注射液、氟尿嘧啶注射液的新药申请(NDA)均已获得批准。这标志着公司具备了在 美国市场销售产品的资格，有利于公司拓展美国市场的销售、强化产品供应链、丰富产品梯队，为国际 市场的可持续发展进一步夯实了基础。 ...

Core Points - The National Organization for Drug Procurement has canceled the procurement qualification of Ningbo Dahongying Pharmaceutical's fluorouracil injection due to quality issues, placing the company and its contract manufacturer on a violation list, prohibiting them from participating in national drug procurement from October 15, 2025, to April 14, 2027 [1][5] - This incident highlights ongoing quality control issues within the pharmaceutical industry, despite existing regulations and oversight mechanisms [2][8] - The cancellation of procurement qualifications serves as a warning to other companies about the importance of maintaining drug quality to avoid losing market share and damaging brand reputation [2][8] Industry Impact - The fluorouracil injection, a widely used chemotherapy drug, had a market size of approximately $30 million in the U.S. and about 550 million yuan in China in 2023 [4] - The competitive landscape for fluorouracil injection saw seven companies successfully bid in the tenth national procurement, with Ningbo Dahongying's bid price being 2.97 yuan for a 10ml:0.25g specification [4] - The cancellation of procurement qualifications for multiple products indicates a broader trend of quality issues affecting various pharmaceutical companies, including Jiangxi Jingrui and Shanxi Yanghe [5][6] Regulatory Environment - The regulatory framework for drug procurement has been evolving, with the upcoming eleventh batch of national drug procurement set to impose stricter quality control measures, including requiring companies to have at least two years of experience in producing similar formulations [8][9] - The emphasis on quality in the procurement process is expected to benefit companies with stable production processes and strict quality controls, potentially raising the overall quality standards in the industry [9][10] Strategic Recommendations - Companies are encouraged to balance quality and cost-effectiveness by optimizing production processes, increasing R&D investment, expanding market reach, and establishing stable supply chains [10] - Engaging in national drug procurement with a focus on quality assurance and reasonable pricing strategies can help companies gain market share and build patient trust [10]